EGFR突变NSCLC软脑膜转移脑脊液cfDNA的独特基因图谱:液体活检新介质
本研究对28例EGFR突变伴软脑膜转移的NSCLC患者进行脑脊液cfDNA、脑脊液沉淀和血浆的二代测序。脑脊液cfDNA驱动基因检出率100%,且等位基因分数更高,可捕获血浆和组织未见的独特拷贝数变异及TP53杂合性缺失。脑脊液cfDNA应视为该人群软脑膜转移最具代表性的液体活检介质。
要点
- 脑脊液cfDNA驱动基因检出率100%,高于脑脊液沉淀84.6%和血浆73.1%。
- 脑脊液cfDNA中MET拷贝数增益占47.8%,TP53杂合性缺失占73.1%。
- TKI进展患者脑脊液cfDNA中EGFR T790M检出率为30.4%。
核心结论
- 脑脊液cfDNA可揭示EGFR突变NSCLC软脑膜转移的独特基因图谱,应视为该场景最具代表性的液体活检介质。
研究设计与样本
- 对45例疑似软脑膜转移患者行腰椎穿刺,纳入确诊软脑膜转移且EGFR突变者28例。
- 采用二代测序检测原发肿瘤、脑脊液和血浆样本,26例分别有脑脊液和血浆可用。
主要发现
- 脑脊液cfDNA、脑脊液沉淀和血浆的驱动基因检出率分别为100%(26/26)、84.6%(22/26)和73.1%(19/26)。
- 92.3%(24/26)患者脑脊液cfDNA等位基因分数高于脑脊液沉淀和血浆。
- 脑脊液cfDNA主要检出多个拷贝数变异,MET拷贝数增益最常见,占47.8%(11/23),其他包括ERBB2、KRAS、ALK和MYC。
- 脑脊液cfDNA中TP53杂合性缺失占73.1%(19/26),显著高于血浆的7.7%(2/26,P < 0.001)。
- TP53杂合性缺失患者合并耐药突变频率有更高趋势(70.6% 对 33.3%;P = 0.162)。
关键数值与推荐
- TKI进展患者脑脊液cfDNA中EGFR T790M检出率为30.4%(7/23)。
临床怎么用
- 对EGFR突变NSCLC疑似软脑膜转移患者,脑脊液cfDNA可作为优先的液体活检介质用于基因分型。
局限性
- 样本量较小(28例),脑脊液和血浆配对可用者26例。
- TP53杂合性缺失与合并耐药突变频率的比较仅为趋势性差异(P = 0.162)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Leptomeningeal metastases (LM) are more frequent in non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Due to limited access to leptomeningeal lesions, the purpose of this study was to explore the potential role of cerebrospinal fluid (CSF) as a source of liquid biopsy in patients with LM. PATIENTS AND METHODS: Primary tumor, CSF, and plasma in NSCLC with LM were tested by next-generation sequencing. In total, 45 patients with suspected LM underwent lumbar puncture, and those with EGFR mutations diagnosed with LM were enrolled. RESULTS: A total of 28 patients were enrolled in this cohort; CSF and plasma were available in 26 patients, respectively. Driver genes were detected in 100% (26/26), 84.6% (22/26), and 73.1% (19/26) of samples comprising CSF cell-free DNA (cfDNA), CSF precipitates, and plasma, respectively; 92.3% (24/26) of patients had much higher allele fractions in CSF cfDNA than the other two media. Unique genetic profiles were captured in CSF cfDNA compared with those in plasma and primary tissue. Multiple copy number variations (CNVs) were mainly identified in CSF cfDNA, and MET copy number gain identified in 47.8% (11/23) of patients was the most frequent one, while other CNVs included ERBB2, KRAS, ALK, and MYC. Moreover, loss of heterozygosity (LOH) of TP53 was identified in 73.1% (19/26) CSF cfDNA, which was much higher than that in plasma (2/26, 7.7%; P < 0.001). There was a trend towards a higher frequency of concomitant resistance mutations in patients with TP53 LOH than those without (70.6% versus 33.3%; P = 0.162). EGFR T790M was identified in CSF cfDNA of 30.4% (7/23) of patients who experienced TKI progression. CONCLUSION: CSF cfDNA could reveal the unique genetic profiles of LM and should be considered as the most representative liquid biopsy medium for LM in EGFR-mutant NSCLC.
引用
- Li YS, Jiang BY, Yang JJ, et al. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy. Ann Oncol. 2018. PMID: 29346604. doi:10.1093/annonc/mdy009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。